AttendMe Owl Logo
AttendMe
Evidence Evolution
NephrologyNephrology

How This Evidence Evolved

IgA Nephropathy Treatment

From supportive care to targeted immunosuppression and novel endothelin-angiotensin blockade

13.3

Timeline

Signal

Early observations and pilot data that first suggested a new direction

STOP-IgAN randomized 162 patients with persistent proteinuria despite optimized supportive care to continued supportive care or added immunosuppression. At 3 years, full clinical remission occurred in 17% with immunosuppression versus 5% with supportive care (p=0.01). An eGFR decrease of at least 15 mL/min/1.73 m² occurred in 26% versus 28% (p=0.75). Severe infections were more frequent with immunosuppression, and one patient died of sepsis. The annual eGFR decline did not differ significantly.
Proof

Landmark RCTs and pivotal trials that established the evidence base

TESTING enrolled 503 patients with high-risk IgA nephropathy after optimized background care. Excess serious infections prompted a lower methylprednisolone dose and pneumocystis prophylaxis. Over mean follow-up of 4.2 years, the composite kidney endpoint occurred in 28.8% with methylprednisolone versus 43.1% with placebo (HR 0.53, 95% CI 0.39–0.72). The reduced-dose subgroup HR was 0.27 (95% CI 0.11–0.65). Serious adverse events were more frequent with methylprednisolone, mainly with full-dose therapy.
Extension

Follow-up studies, subgroup analyses, and real-world validation

PROTECT compared sparsentan, a non-immunosuppressive dual endothelin angiotensin receptor antagonist, with irbesartan. The final analysis included 404 treated patients. At 110 weeks, proteinuria change was −42.8% with sparsentan versus −4.4% with irbesartan. Chronic eGFR slope from weeks 6–110 was −2.7 versus −3.8 mL/min/1.73 m²/year (p=0.037). The total slope difference from day 1 to week 110 did not meet conventional statistical significance (p=0.058).
Now

Current standard of care and ongoing research directions

In PROTECT, proteinuria changed −42.8% with sparsentan versus −4.4% with irbesartan at 110 weeks, a secondary outcome. Targeted trials tested APRIL-neutralizing sibeprenlimab (phase 2), dual BAFF/APRIL atacicept (phase 2b), and factor B inhibitor iptacopan (phase 3 interim); proteinuria fell versus placebo.

Landmark Trials in This Story

STOP-IgAN2015Landmark

Intensive Supportive Care plus Immunosuppression in IgA Nephropathy

3-y immunosuppression/supportive care: remission 17%/5% (P=.01); eGFR fall ≥15 mL/min/1.73m²: 26%/28% (P=.75)

New England journal of medicineRCTN=162
TESTING2022Landmark

Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial

Composite kidney endpoint over mean 4.2 years: methylprednisolone 28.8% vs placebo 43.1% (HR 0.53, 95% CI 0.39–0.72)

JAMARCTN=503
PROTECT2023Landmark

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

404 treated; primary: proteinuria change at 36 weeks. Secondary chronic eGFR slope: sparsentan −2.7 vs irbesartan −3.8 mL/min/1.73m²/year.

LancetRCTN=404
ENVISION sibeprenlimab2024

A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy.

12-month UPCR geometric mean reduction: sibeprenlimab 2/4/8 mg/kg 47.2%/58.8%/62.0% vs placebo 20.0%

The New England journal of medicineRandomized double-blind placebo-controlled phase 2 trialN=155
ORIGIN atacicept2024

A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy.

Week 24 UPCR change: combined 75/150 mg atacicept −31% vs placebo −8%; reported 25% relative reduction

Kidney internationalRandomized double-blind placebo-controlled phase 2b trialN=116
APPLAUSE-IgAN interim analysis2025

Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy.

Month 9 UPCR: iptacopan 38.3% lower than placebo (95% CI 26.0–48.6); efficacy analysis first 250 randomized

The New England journal of medicineRandomized double-blind phase 3 trial; prespecified interim efficacy analysis

Explore the evidence yourself

Ask AttendMe about any trial, guideline, or clinical question. Evidence-ranked answers from 3.7M+ peer-reviewed articles.

Related Evidence

Frequently Asked Questions

What is sparsentan and why is it significant for IgA nephropathy?+
Sparsentan is a non-immunosuppressive dual endothelin angiotensin receptor antagonist. PROTECT’s final analysis included 404 treated patients. At 110 weeks, proteinuria change was −42.8% with sparsentan versus −4.4% with irbesartan. Chronic eGFR decline was slower with sparsentan, while the total eGFR slope difference had p=0.058.
Are corticosteroids effective in IgA nephropathy?+
TESTING enrolled 503 patients and found the composite kidney outcome in 28.8% with methylprednisolone versus 43.1% with placebo over mean 4.2-year follow-up (HR 0.53, 95% CI 0.39–0.72). Serious adverse events increased, mainly with full-dose therapy. The protocol added pneumocystis prophylaxis after excess serious infections. STOP-IgAN found no significant difference in annual eGFR decline with added immunosuppression.

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice. Clinical decisions should always be based on individual patient assessment, local guidelines, and professional judgement.

All data sourced from published, peer-reviewed articles and clinical practice guidelines.

Claims checked against cited sources: 10 November 2026